FDA Approves Merck’s Keytruda Combo for Early Breast Cancer Treatment

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

Merck & Co Inc. said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of tough-to-treat breast cancer in combination with chemotherapy.

The FDA approval is for treating triple-negative breast cancer (TNBC), an aggressive form of the disease with an increased risk of recurrence.